BTK and B-cell chronic lymphocytic leukemia: Where access allows, most CLL patients will now cycle through time-limited venetoclax-based therapy (including potentially re-treatment) and continuous covalent BTK inhibition (cBTKi) with or without anti-CD20 monoclonal antibody.